Table 1 Baseline characteristics of 273 patients with liver dysfunction in ADACS
Category | Scheduled monitoring group (n = 111) | Passive detection group (n = 162) | P value |
|---|---|---|---|
Age, median years (IQR) | 40(29,53) | 40(28,55) | 0.243 |
Male | 89(80.2%) | 123(75.9%) | 0.407 |
Married | 86(77.5%) | 130(80.1%) | 0.697 |
Income per year, median¥(IQR) | 10000(5000,20000) | 10000(5000,15000) | 0.647 |
Weight | |||
<50 kg | 27(24.3%) | 44(27.2%) | 0.600 |
≥50 kg | 84(75.7%) | 118(72.8%) | |
Type of anti-TB treatment | |||
Primary treatment | 95(85.6%) | 143(88.3%) | 0.514 |
Re-treatment | 16(14.4%) | 19(11.7%) | |
History of anti-TB adverse reactions | |||
Yes | 3(2.7%) | 2(1.2%) | 0.668 |
No | 108(97.3%) | 160(98.8%) | |
History of liver diseases* | |||
Yes | 7(6.3%) | 9(5.6%) | 0.795 |
No | 104(93.7%) | 153(94.4%) | |
HBSAg positive | 21(18.9%) | 32(19.8%) | 0.940 |
Pattern of taking anti-TB drugs | |||
Every day | 9(8.1%) | 17(10.5%) | 0.510 |
Every other day | 102(91.9%) | 145(89.5%) | |
Usage of preventive liver protective drugs | |||
Finished manufactured herbal preparations | 57(51.4%) | 59(36.4%) | 0.145 |
Combinations of vitamins & other non-herbal substances | 3(2.7%) | 5(3.1%) | |
Pharmaceutical preparations | 5(4.5%) | 7(4.3%) | |
Combinations of above drugs | 10(9.0%) | 23(14.2%) | |